-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 GcrdQU+t5sKQpWP/40y3LpTNucz0C3QMMDxLmgBP2JJ+RYiQnuGpdI4Aar2cZy2X
 X6qOPFA2B5GIA6vJPqiJcQ==

<SEC-DOCUMENT>0000950123-11-002396.txt : 20110113
<SEC-HEADER>0000950123-11-002396.hdr.sgml : 20110113
<ACCEPTANCE-DATETIME>20110112175327
ACCESSION NUMBER:		0000950123-11-002396
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110111
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110113
DATE AS OF CHANGE:		20110112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		11526161

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c10983e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV
style="width: 7.5in; font-family: 'Times New Roman',Times,serif; margin-left: 0.25in">
<DIV style="font-size: 10pt">
<DIV
style="border-bottom: black 2pt solid; width: 100%; font-size: 1pt">&nbsp;</DIV>
<DIV
style="border-bottom: black 1pt solid; width: 100%; font-size: 1pt">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): January 11, 2011</B>

<P style="font-size: 24pt" align="center"><B>CYCLACEL PHARMACEUTICALS,
INC.<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="text-align: center; font-size: 10pt" border="0" cellspacing="0"
cellpadding="0" width="100%">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>0-50626</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>91-1707622</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="text-align: center; font-size: 10pt" border="0" cellspacing="0"
cellpadding="0" width="100%">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>200 Connell Drive, Suite
1500<BR>
Berkeley Heights, NJ<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>07922</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(908) 517-7330</B>
<TABLE style="text-align: center; font-size: 10pt" border="0" cellspacing="0"
cellpadding="0" width="30%">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<DIV
style="border-bottom: black 1pt solid; margin-top: 10pt; width: 100%; font-size: 1pt">&nbsp;</DIV>
<DIV
style="border-bottom: black 2pt solid; width: 100%; font-size: 1pt">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="width: 7.5in; font-family: 'Times New Roman',Times,serif; margin-left: 0.25in">

<P style="font-size: 10pt" align="left"><B>Item&nbsp;8.01 Other Events.</B>

<P style="text-indent: 4%; font-size: 10pt" align="left">On January&nbsp;11,
2011, Cyclacel Pharmaceuticals, Inc. (the &#8220;<B>Company</B>&#8221;) issued
a press release announcing that it has opened enrollment of the SEAMLESS
pivotal Phase 3 trial for the Company&#8217;s sapacitabine oral capsules as a
front-line treatment of elderly patients aged 70&nbsp;years or older with newly
diagnosed acute myeloid leukemia (AML)&nbsp;who are not candidates for
intensive induction chemotherapy. The study is being conducted under a Special
Protocol Assessment agreement that the Company reached with the U.S. Food and
Drug Administration. A copy of the press release is attached as
Exhibit&nbsp;99.1 to this Current Report on Form 8-K, and the information
contained therein is incorporated herein by reference.

<P style="text-indent: 4%; font-size: 10pt" align="left">Neither the filing of
the press release as an exhibit to this Report nor the inclusion in the press
release of a reference to our internet address shall, under any circumstances,
be deemed to incorporate the information available at our internet address into
this Report. The information available at our internet address is not part of
this Report or any other report filed by us with the Securities and Exchange
Commission.

<P style="font-size: 10pt" align="left"><B>Item&nbsp;9.01 Financial Statements
and Exhibits.</B>

<P style="text-indent: 4%; font-size: 10pt"
align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (d)&nbsp;Exhibits

<DIV align="center">
<TABLE style="font-size: 10pt" border="0" cellspacing="0" cellpadding="0"
width="100%">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="18%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="77%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->

 <TR valign="bottom">
  <TD valign="top">
<DIV
style="text-indent: 0px; margin-left: 0px"><B>Exhibit<BR>
Number</B>&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left"><BR>
<B>Description</B></TD>
 </TR>
 <TR style="font-size: 1px">
  <TD style="border-top: #000000 1px solid" valign="top">
<DIV style="text-indent: 0px; margin-left: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD style="border-top: #000000 1px solid" valign="top"
align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="text-indent: 0px; margin-left: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="text-indent: 0px; margin-left: 0px">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press release, dated January&nbsp;11, 2011</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="width: 7.5in; font-family: 'Times New Roman',Times,serif; margin-left: 0.25in">

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="text-indent: 4%; font-size: 10pt" align="left">Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.

<P style="margin-left: 46%; font-size: 10pt" align="left"><B>CYCLACEL
PHARMACEUTICALS, INC.</B>

<P style="margin-left: 46%; font-size: 10pt" align="left">By: <U><B>/</B>s/
Paul
McBarron&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
Name:
Paul McBarron<BR>
Title: Executive Vice President&#8212;Finance,<BR>
Chief
Financial Officer and<BR>
Chief Operating Officer<BR>


<P style="font-size: 10pt" align="left">Date: January&nbsp;12, 2011

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c10983exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="width: 7.5in; font-family: Arial,sans-serif; margin-left: 0.25in">

<P style="font-size: 10pt" align="right"><B>Exhibit 99.1</B>

<P style="font-size: 10pt" align="center"><IMG src="c10983p1098301.jpg" alt="CYCLACEL LETTERHEAD">

<P style="font-size: 10pt" align="center"><B>CYCLACEL BEGINS PIVOTAL PHASE 3
&#8220;SEAMLESS&#8221; TRIAL OF SAPACITABINE AS<BR>
FRONT-LINE TREATMENT FOR
AML UNDER A SPECIAL PROTOCOL ASSESSMENT</B>

<P style="font-size: 10pt" align="center"><B><I>- Cyclacel to host conference
call at 4:30 pm ET on Tuesday, January&nbsp;18, 2011 to discuss study design
- -</I></B>

<P style="font-size: 10pt" align="justify"><B>Berkeley Heights, NJ,
January&nbsp;11, 2011 </B>&#8211; Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC,
NASDAQ: CYCCP; &#8220;Cyclacel&#8221; or the &#8220;Company&#8221;), today
announced that it has opened enrollment of the SEAMLESS pivotal Phase 3 trial
for the Company&#8217;s sapacitabine oral capsules as a front-line treatment of
elderly patients aged 70&nbsp;years or older with newly diagnosed acute myeloid
leukemia (AML)&nbsp;who are not candidates for intensive induction
chemotherapy. The study is being conducted under a Special Protocol Assessment
(SPA)&nbsp;agreement that Cyclacel reached with the U.S. Food and Drug
Administration (FDA). SEAMLESS builds on promising 1-year survival observed in
elderly patients aged 70&nbsp;years or older with newly diagnosed AML or AML in
first relapse enrolled in a Phase 2 study of single agent sapacitabine.

<P style="font-size: 10pt" align="justify">&#8220;The opening of the SEAMLESS
study for patient enrollment marks an important milestone for Cyclacel as this
is the first pivotal Phase 3 trial ever conducted by the Company,&#8221; said
Spiro Rombotis, President and Chief Executive Officer of Cyclacel. &#8220;If it
reaches the market, sapacitabine will become an important treatment option for
many elderly patients who are suffering from this life-threatening disease. We
also look forward to interim data from the Phase 2 study of sapacitabine in
Non-Small Cell Lung Cancer (NSCLC). Sapacitabine may be one of few cancer drugs
with activity against both hematological malignancies and solid tumors.&#8221;

<P style="font-size: 10pt" align="justify">The SEAMLESS study is chaired by
Hagop M. Kantarjian, M.D., Chairman and Professor, Department of Leukemia, The
University of Texas MD Anderson Cancer Center, Houston, Texas. SEAMLESS is a
multicenter, randomized, Phase 3 study comparing three treatment arms. In Arm A
sapacitabine is administered in alternating cycles with decitabine, in Arm B
sapacitabine is administered alone and in Arm C decitabine is administered
alone. The primary efficacy endpoint is overall survival. The study is designed
to demonstrate an improvement in overall survival of either of two pairwise
comparisons: (1)&nbsp;Arm A versus Arm C or (2)&nbsp;Arm B versus Arm C.
Approximately 150 patients per arm or a total of 450 patients from
approximately 50 centers will be enrolled. SEAMLESS will be monitored by a Data
Safety Monitoring Board (DSMB). A prespecified interim analysis for futility
will be performed and reviewed by the DSMB.

<P style="font-size: 10pt" align="justify">&#8220;We chose decitabine as an
active control arm as it is one of the treatment options recommended by the
National Comprehensive Cancer Network&#8217;s Clinical Practice Guidelines. We
are pleased to learn that this active control arm is acceptable to AML
investigators.&#8221; said Judy Chiao, M.D., Vice President of Clinical
Development and Regulatory Affairs of Cyclacel. &#8220;AML in the elderly is a
life-threatening disease with high unmet medical need. Patients with AML aged
70&nbsp;years or older have a poor prognosis, as the majority of these patients
are not candidates for intensive induction chemotherapy because of poor
tolerability to such therapy and a high risk of relapse because of the lack of
effective consolidation and maintenance therapy. If the SEAMLESS study is
successful, sapacitabine may significantly improve the outcome of this
devastating disease in elderly patients.&#8221;

<P style="font-size: 10pt" align="justify">The treatment regimen of
sapacitabine administered in alternating cycles with decitabine has been found
to be safe and efficacious in an on-going pilot study conducted at The
University of Texas MD Anderson Cancer Center. In addition, SEAMLESS
has a lead-in stage to further confirm the safety and efficacy of the
alternating treatment regimen in the multicenter setting.


<P style="font-size: 10pt" align="left"><FONT  style="font-family: Wingdings">&#254;</FONT> 200 Connell Drive, Suite&nbsp;1500, Berkeley
Heights, NJ&nbsp; 07922 USA T: +1 (908)&nbsp;517 7330 F: +1 (866)&nbsp;271
3466<BR>
<FONT  style="font-family: Wingdings">&#168;</FONT> Dundee Technopole, James Lindsay
Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382 206 067

<P style="margin-top: 0pt; font-size: 10pt" align="center"><U>www.cyclacel.com</U> &#8211; <U>info@cyclacel.com</U>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 7.5in; font-family: Arial,sans-serif; margin-left: 0.25in">

<P style="font-size: 10pt" align="justify">The FDA has designated sapacitabine
as an orphan drug for the treatment of both AML and myelodysplastic syndromes
(MDS).

<P style="font-size: 10pt" align="justify"><B>Conference call and Webcast
Information:</B>

<P style="font-size: 10pt" align="justify">Cyclacel management will review the
SEAMLESS trial design on a conference call scheduled for January&nbsp;18, 2011
at 4:30 p.m. Eastern. Conference call and webcast details are as follows:

<P style="font-size: 10pt" align="justify">US/Canada call: (877)&nbsp;493-9121/
international call: (973)&nbsp;582-2750 <BR>
US/Canada archive:
(800)&nbsp;642-1687 / international archive: (706)&nbsp;645-9291 <BR>
Code for
live and archived conference call is 36660893.

<P style="font-size: 10pt" align="justify">Webcast: For the live and archived
webcast, please visit the Corporate Presentations page on the Cyclacel website
at <U>www.cyclacel.com</U>. The webcast will be archived for 90&nbsp;days and
the audio replay for 7&nbsp;days.

<P style="font-size: 10pt" align="justify"><B>About Acute Myeloid Leukemia
(AML)</B>

<P style="font-size: 10pt" align="justify">AML is a cancer of the blood cells
that progresses rapidly and if not treated, could be fatal in a few months. AML
is generally a disease of older people and is uncommon before the age of 40.
The average age of a patient with AML is about 67&nbsp;years. There are more
than 12,300 new cases of AML, of which about half are elderly, and nearly 9,000
deaths caused by this cancer each year in the United States. A recently
published review of The University of Texas MD Anderson Cancer Center&#8217;s
historical experience with front-line intensive induction chemotherapy for
elderly AML patients aged 70&nbsp;years or older demonstrated that while 45% of
patients achieved a complete remission, median overall survival was only
4.6&nbsp;months and 36% of patients died within the first 8&nbsp;weeks of
treatment, underscoring the unmet need in this patient setting (Kantarjian, H,
et al, Blood, DOI 10.1182/blood-2010-03-276485).

<P style="font-size: 10pt" align="justify"><B>About Special Protocol Assessment
(SPA)</B>

<P style="font-size: 10pt" align="justify">A Special Protocol Assessment is a
binding written agreement with the FDA that the sponsor&#8217;s proposed trial
protocol design, clinical endpoints and statistical analyses are acceptable to
support regulatory approval. Final marketing approval depends on efficacy
results, adverse event profile and an evaluation of the benefit/risk of a
treatment as demonstrated in the trial. For further information regarding the
SPA process, please visit the FDA website, www.fda.gov.

<P style="font-size: 10pt" align="justify"><B>About sapacitabine</B>

<P style="font-size: 10pt" align="justify">Sapacitabine (CYC682), an
orally-available nucleoside analogue, is currently being evaluated in a Phase 3
trial in elderly AML under a SPA agreement with the U.S. Food and Drug
Administration and Phase 2 trials in patients with hematological malignancies
and solid tumors. Sapacitabine acts through a dual mechanism, interfering with
DNA synthesis by causing single-strand DNA breaks and inducing arrest of cell
cycle progression mainly at G2-Phase. Both sapacitabine and CNDAC, its major
metabolite, have demonstrated potent anti-tumor activity in preclinical
studies. Over 200 patients have received sapacitabine in Phase 2 studies in
AML, MDS, cutaneous T cell lymphoma (CTCL)&nbsp;and NSCLC. Sapacitabine has
been administered to approximately 170 patients in five Phase 1 studies with
both hematological malignancies and solid tumors. In December&nbsp;2009 at the
51st Annual Meeting of the American Society of Hematology (ASH), Cyclacel
reported data from a randomized Phase 2 study including promising 1-year
survival in elderly patients with AML aged 70&nbsp;years or older.
Sapacitabine is part of Cyclacel&#8217;s pipeline of small molecule drugs
designed to target and stop uncontrolled cell division.

<P style="font-size: 10pt" align="center">2

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 7.5in; font-family: Arial,sans-serif; margin-left: 0.25in">

<P style="font-size: 10pt" align="justify"><B>About Cyclacel Pharmaceuticals,
Inc.</B>

<P style="font-size: 10pt" align="justify">Cyclacel is a biopharmaceutical
company developing oral therapies that target the various phases of cell cycle
control for the treatment of cancer and other serious diseases. Sapacitabine
(CYC682), a cell cycle modulating nucleoside analog, is in Phase 3 development
for the treatment of acute myeloid leukemia in the elderly under a Special
Protocol Assessment agreement with the U.S. Food and Drug Administration, and
is in Phase 2 studies for myelodysplastic syndromes and lung cancer. Seliciclib
(CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in
Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and
in a Phase 1 trial in combination with sapacitabine. Cyclacel&#8217;s ALIGN
Pharmaceuticals subsidiary markets directly in the U.S. Xclair&#174; Cream for
radiation dermatitis, Numoisyn&#174; Liquid and Numoisyn&#174; Lozenges for
xerostomia. Cyclacel&#8217;s strategy is to build a diversified
biopharmaceutical business focused in hematology and oncology based on a
portfolio of commercial products and a development pipeline of novel drug
candidates. Please visit <U>www.cyclacel.com</U> for additional information.

<P style="font-size: 10pt" align="justify"><B>Forward-looking Statements</B>

<P style="font-size: 10pt" align="justify">This news release contains certain
forward-looking statements that involve risks and uncertainties that could
cause actual results to be materially different from historical results or from
any future results expressed or implied by such forward-looking statements.
Such forward-looking statements include statements regarding, among other
things, the efficacy, safety, and intended utilization of Cyclacel&#8217;s
product candidates, the conduct and results of future clinical trials, plans
regarding regulatory filings, future research and clinical trials and plans
regarding partnering activities. Factors that may cause actual results to
differ materially include the risk that product candidates that appeared
promising in early research and clinical trials do not demonstrate safety
and/or efficacy in larger-scale or later clinical trials, the risk that
Cyclacel will not obtain approval to market its products, the risks associated
with reliance on outside financing to meet capital requirements, and the risks
associated with reliance on collaborative partners for further clinical trials,
development and commercialization of product candidates. You are urged to
consider statements that include the words &#8220;may,&#8221;
&#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221;
&#8220;should,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221;
&#8220;projects,&#8221; &#8220;potential,&#8221; &#8220;expects,&#8221;
&#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221;
&#8220;continues,&#8221; &#8220;forecast,&#8221; &#8220;designed,&#8221;
&#8220;goal,&#8221; or the negative of those words or other comparable words to
be uncertain and forward-looking. For a further list and description of the
risks and uncertainties the Company faces, please refer to our most recent
Annual Report on Form 10-K and other periodic and current filings that have
been filed with the Securities and Exchange Commission and are available at
<U>www.sec.gov</U>. Such forward-looking statements are current only as of the
date they are made, and we assume no obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise.

<P style="font-size: 10pt" align="justify"><B>Contact for Cyclacel
Pharmaceuticals, Inc.</B>

<P style="font-size: 10pt" align="justify">Investors/Media: <BR>
Corey Sohmer,
(908)&nbsp;517-7330 <BR>
<U>csohmer@cyclacel.com</U>

<P style="font-size: 10pt" align="justify">&#169; Copyright 2011 Cyclacel
Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel&#174;
are trademarks of Cyclacel Pharmaceuticals, Inc. Numoisyn&#174; and
Xclair&#174; are trademarks of Sinclair Pharma plc.

<P style="font-size: 10pt" align="center">3

<P style="display: none; font-size: 10pt" align="center">3
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c10983p1098301.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c10983p1098301.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP!#``,"`@,"`@,#`P,$`P,$!0@%!00$!0H'!P8(#`H,#`L*
M"PL-#A(0#0X1#@L+$!80$1,4%145#`\7&!84&!(4%13_VP!#`0,$!`4$!0D%
M!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!3_P``1"`!Y`M`#`2(``A$!`Q$!_\0`'P```04!`0$!`0$`
M``````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0```%]`0(#``01
M!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT
M-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)
MBI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9
MVN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0````````$"
M`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A
M<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$
M149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7
MF)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;G
MZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]4Z3-!Z5A>+/%=IX0TI[RZ)9B
M=L4*_>D;L!_C5PA*<E&*NV1.<:<7.;LD:&I:I:Z1;/<WEQ';0)UDD;`KS37O
MCK:VSLFE6376./.N#L0_0=:Y*"Q\1?%S57N99/*LXS_K'R((1Z*/XC[_`*U<
MNI/!7@HF%(&\2ZFG#/(W[I6_E^'->_2P5&D^6HG.?9;+U?\`P3Y>OF%>LN:D
MU3I_S/=^BU_+YE6Z^-'B6Z;,,MO;+Z10;_Y@TVV^-'B:W<^=<6]R.PE@"?R`
MJVGQ!\07*DZ5X>MK2('_`)=[(MGZU5N?'NK0Y76O#UC<QMU^T69C./9A7HJC
M#X?8Q^]7_+]3RG7J?%]8EZV=OS_0ZG1/CM#-(L>K6#6X/_+:V.]1]5ZUZ;I.
ML6>MVB75C<QW,#='0Y_`^E>!1VOA7Q40EHTGAO47^Y',_F6TC>@;JN:H6]QK
MWPXUP!%DM[G()B&7BN%SVQPP/KUKCJY?1JW5+W)=G_7Y'H4,TKT+.M[\.Z_I
M?BD?36:6J=G>"YBCW82<QJ[P[@63([BK8KYC;0^O3NKBT444#"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`(GD$:,S'"J,DGL*\/:"Y^,'CJ4[VCT>T^7<.@CSV_VF
M_E7H7Q5UAM'\%7[1G$LX%NI!Y&XX.*YV%/\`A7/PG$L2A=2O57![F23A1^`P
M*]C!ITZ?M(_')\L?+NSP,>U6J*E/X(KFEY]D4/$6J7/B+41X-\*1BVT^V&RX
MGC^50!U&1_"._<FLZ!=)\+78TOP_I8\3Z^ORR74J[HHF]`.G^>M:ATJX\)^'
M--\/:9QX@USYKBX_BC3&6)^@./KGUJ5;5-+BN=$\/3II=C9+G5M=D&6W=T4]
MS_+/KU[XRBH\L?A_/HY2:ULWHEU/-E"<I<\_B_+JHQ3T32U;>Q4O+7QG+AM3
M\466BJ>!`LRJ5]!@#^M0K#XWM8"UGJ]IXCMARUNLB3EA[JPS^M36'A2ROH_-
MTWPE/K,;<C4-9N3&9?<+UP>V15*]\.:=:7D*7&E7G@N_D(6"\MY3+;,_8,1R
M,G%7&4;\MEZ<L?R3YOU)E":7-=^O-+\W'E_3S,E++2?&MPUG':KX>\1$X$!!
M%O<-W7!Y1OTKJ;#QKI'PJM=)T7QKJL$>I7,A:SC=?-\B/.`2^.!GO5B>?^S7
MM[+4I-*F^),]M</HRONS<;%.&;``/N3530?A/+\2='T?5?BAI,#^)K&5PHMW
MVJT6[*K(`2#Z\&O,Q>+YU[*&WWZ^3WL>O@<#[-^VJ?$_EIYK:_H<!X`^#7Q#
MT;XYR:[?WC?V8+F2::]^TEA=1$_*FWW]#PO:OJ)>E-V`=!CM1DC&<9S7D'N#
MZ*C!/^12YH`?13,FDW<]J`)**9D__KI<T`.HIK'%)DT`/HII/%-W<]C]!0!)
M13`:,GT_2@!]-.<]:3)_R*,F@`!YZT^N&MO'-[-XA6Q-@PA,ZQ^;CC![?[R]
M3[5V^:`'44E+0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!112&@!:*CW$'_`4
M!C_^L4`244U3S2,2#0`^BF@TZ@`HIK9QQ2`F@!]%1[_8_P#?)I=W'_UJ`'T4
M@I:`"BBB@`HHHH`**1L]J9N/L?H*`)**C!/M2[L&@!]%1[CFG"@!U%,)(H&:
M`'T444`>:?&8-<Q>'K+_`)9W-^%<#V&15KXA6ZWFN^$--9/W$EZ68>R+D"E^
M+5N!:Z)?MP+348R2>@#?+S5SQR@AU?POJ!XC@O\`RW;T#K@?J*]BE*T*5O[_
M`-_]6/!K1O.M?O#[K_\`#E*27_BLO%.J$;I-,L4@AR>A*ES^I%1Z%X>2Z&D:
M9,HEM((!J5V#_P`M[B0Y7=Z@?,?P'I6A-I__`!4GB.T(VOJ5FDT1S]X@%"/P
MPOYU<T"94EL;@_=N;5+=F/:6/(VG\V_*HE4:A[O9?E_P_P`RXTU*?O\`=_\`
MI7_[/R.E`Q]!61J^HR^<EK964>I3K+$9XI3L6*)CS("00Q`!.!S6N#1QZ5Y1
M[1AZ!X332ECDOKN36[^*25HKZ]1#-$CG.Q6`X4#CZ5O!<4@ZTX4#$;@<]*\*
M@\1>*OC?XKUFS\/:R_A?PAI%P;274+5`US>3#[P4GA5]_0CZ5[G<(9(74=2"
M!GZ5X5^RWJ46FZ?XD\*786VUS3-4F::W8X=T;HX'<9XS]*`.QT#X27GAW44G
M3QIKU[9M&Z7%G>RK(LI88W`XRI'48K!^$7B;5O#/B_6OA[XHO9;Z^M2;S2K^
MY;+75J>Q/<K_`/%>E>Q=?_UUX;^UEHT:>#=/\16TLMEK.G7:P6]Y`=KB.4%7
M7/IC^OK0!>\.^(=0^)7Q/U+6H-1GL_`_AK?;1B)ML=]<@?O&;U1/Y@>M9GAZ
M_P#%OQ\NM0U*TUZ?PEX-@N'M[1;!5-S>%>&9F/1?I_C7H6B^#;70_A0/#^CP
MB-#ICQ1`GEI'C/)/J6;K7'?LJ:W:W'PQ@T3Y(M5T::2VO+;I(I#'#$>AYY]J
M`.N\%_#:\\&ZRUPOBS6-6L'B*&PU)UE57Z[PV`<^U<[^S7KVH^(/!FIW&I7T
MU_,FJW,:R3MDA0QP/H*];'4>E>+?LI\>`]5_[#-U_P"AF@#VAG"J2QP!R37R
MW>_$CQ+_`,)7+\18]4N!X(AUU='_`+/3F.2WP$,P^K_K7KWQ]\8R^#_AOJ+6
M98ZK?XL+)(^7,LG&5'<@<UY;'J-V/@Z/`9^&7BA8C8FW:98H\><1DR#YL_?R
M:`/H+Q-XFLO"OAF_UR\D_P!!LX&N'=><J!QCZ\?G7D?A/0O&GQETU/$6N>)+
MWPMH]X2]GHVD@(XASPTDA&=Q]JP8=4U#XH?LH:SIJH[:]IEL]A<VW\9>$CY2
M.OW<9]P:]:^"WB6P\4_#'P_=6$RRI%:1V\BY^9'10I##MTS]"*`,M_".I_#[
MP;XLE'BO5-9B-A(]JM^RL]HRHQRK@9.<CKZ5P/PE^'.L_$#X;Z%X@O/'WB2"
MYO[?S'2*9=@.2../:O9?B/\`\B!XC_[!\_\`Z+->$_!/X*+XI^%/AW4O^$KU
M_3C=6N[[/9W.R*/DC"CL*`.H^.>HZMX+M/AQ96&L7H+ZQ#:W$Y?#W"=]_'.:
M]S`S7@/[2EK]B_X5C;B1YO*UZWCWR'+-@8R?>O?@:`(A9Q"8RB-?,/\`%CGZ
MU+MHS3J`$I:**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*0TM(:`/.O%ML/%
MGQ!T[PQ?O(=&_LZ34)K:*5H_M#B1457*X)49W8!'('TI'M7^$=N9;1Y;WP]<
MWT$?V2:0_P#$M1SM=U<DEEW'<5/3G!K=\6^"GU^\LM3T_49-'UNRW+!>QQB5
M2C??CDC)`=3Z9&#@]JYO6_"$>B>$O$#ZU<:AXCU+6(S;2S6UHQ8Y&V-(XDW"
M-1QSTSR34WY5?^GKM]VGY%63=OZ6F_Z_F7M2^)\MJ-8%KI@NFAU&/2;#]_M%
MU<,`&#''R*K9!(STZ5D^+-5UZ9?#D>L:?'I=PGB*T026-X9H+A"K'Y20K<="
M&4<CC-:FF_#`CX=:9HD][+!JULR7IU%<2.M[G>TISPWSDD@\$&IE^'6HWRV4
MFL>))]2NK;4H;]2MJD40$8($:Q@G;G));))K1+EE9O9K\+?\'Y$)W5^Z?Z_\
M#YF=/\5+[3?&UCHU]I^FV\-Y>_8XH!JBOJ"@J2LSVX7`0[2?O9P1D=JT=!\<
MZYXBNXKVST"&7PW+=/;)<B\Q=!5)5IFB*A=FY6'#EL8.*Q;;X(SVU]!,GB%Q
M%:ZD=3M0;&,RARSLRR2$[I!AR!G&`!Z5M:5\.=1T744CL_$MQ;^'H[EKI-+C
MMU#@L2QC\[.2A=B=N.^,U,=E??\`X;?\=O\`(J6[M_6__`W,31?CE::SXCMK
M-O[,CL;^[DL;18]25[X2+N^:6WP-B'8X!W$_=R!FMKX.2R3_``QTF261Y9#'
M+EG8LQ_>/W/-1Z!\*Y?#VMK-:ZRT>CQ3//%IZ6<2R`L22KS\LZ;F8[<#MSQ7
M1>#O"J^$/#-IHZ7+72VZLHF=`I;+%N@^M)ZTVEN[?J#^+38^>_#%GX>U'X=V
MSZ?9ZS+X[D#?9KJ&&^P+KS#L<RL/)V@XR2=N`:[>Y\8:UX0\5^.K]+"/4K+3
MTLKB],UVT91/L_SB%0I#-WP=H/K7IG@CPHO@SPO8:,ET]XEJA43.NTMEB>@X
M'6LG6/AI'J\?C!&U"2+_`(2**.)B(@?(VQ[,CGYL]>:N_O.VW_!0+5Z_UJ9'
MQ!^*U]X'N'F;3]-738XDD!OM46"YN\XW"WA"MO*YQ\Q7)Z>M1>)?BSJ^CW'B
MN6UT&WNM-\/B,2RR7K)),[HC!441D?Q\Y/I2^)_@FWB/4M9E_MU[:TU6%(YH
M39I)(C(@53'*QRB_*"5`YR>>:T[SX6_VAHWB:RGU:5I==:%Y9Q`H\MDCC0D+
MG'/EYQVS4Q\_ZU7Y*XETO\S*O?B7XJM+_5-//AO3S>6-DNID_P!I/Y9MR6&T
MGRLB7Y#\N-O^U4GBOXMWNBZ'IVL6VGZ;#IUSIZWYEUC55M#(2N[R85"L7D`Z
MYP.1SSQTM_X&2^UG6-0-XZ-J.EKIAC$8(C"F0[P>Y_>=/:N6U#X(F[>W2/7'
MCMO[)BTFY22S25G1$90T3,?W3'=DX!S@4G>W]>?_``/ZT"*77^MO^#_5F:4W
MQ#U?6+F.#PUH<-_-%80ZA=K?79M]@E4F.),(VYR%;KM`XYYK-\8_&Q/"^HO:
MO;Z?:/9V27U_#JNII;2A6R?+@4!A+(`K]PN0!GFKJ_"[5-.CM'T?Q1)IM\+&
M.PN[DV22_:$CR(F"E@$=0S#<,YSTXIVM?"B>\U".]T_7I;*YDMH[6\GN+2.Z
MEG5,[75G_P!7(`S?,`>HXX%4[7TVO_G^'X_B"VU[?Y7^>_D.NOBJ%LO%EW;V
M"S0Z-IT.H0DS8^T"2)I`#Q\OW<9YZUS%_P",]8^U?$5]5M+>]T*QTV"XALEN
MW5B&B+;<A`5W#J03@CC-=#XE^$ESK-QJALO$-QIUKJUBEE?Q&V29I0B%5<.2
M-IPQS@<^U3:I\*&U&3Q$J:Q)#::UIT=C-#]F5BC(FQ9%8GT_AZ4:7O\`U_7]
M:%II6^7_`+;_`,$=>>-]:N=7O;+P[H-OJ<6F1Q&\,]Z879W0.(X1M(9MI'+,
MHSWJC\0/BK?>!KMGETW38]/C2-MM]JJPW=SN(W""$!M^W.#DKD@XR.:TM5^'
M6I-J]U>Z)XDFT,7T<:7J):I,9"BA%=&8CRVVC&0#ZUC^(O@@VOWVL/\`V_-%
M::I'&)DDM$FG5T154K,QR!\@)4`9)//-);I_U_PW;KW,XK2S[?U_6Q2G\<2^
M#+CQWJ!B^U`:U;P(;F9T@MP]M#\\C`-Y<8/4@'&:[OP+XFN?%&CR7=S;V4;)
M,T2S:;?+=VTX`!WQR#!QS@A@""#QC!.5)\.+U;76#:^(9[6^U&[BNVN%MD9-
MRPI$4:,\.C;<E21U]J-"\%ZEX/T]UL+R.\U"^U!;F^G^RI#$R;`I"QAL(,*O
MW<DG)QR::LM'V2_!+_,'KJO/]2/XW7$EO\.KV2*1XG%Q:X:-RIYN(^XYK,NO
MBKJMK=ZE*NA6[Z/INKII-Q<->L)G+M&JNB;,'!D&06'3C-=CXV\*IXT\.SZ2
M]RUHLLD4GFH@8C9(KXP?7;C\:Q[GX81W&EZQ9G495&HZO'JQ<1#,95XGV`9Y
M!\K&>O-$+)^]M?\`^1_2Y3U7]>?ZV&1^.==U76;[^Q]`AO\`1["\^PSS/>>5
M<NX($C1QE=I5<@Y9P3@X'KW(;..U<++\.=1M]9O)M*\2W&E:5?7(N[JRAME9
MS(2"Y28G*!L#(P>_K786%K=6[3FXNA<JTA:("((8T[*3GYOKQ26R_KL)[LS_
M`!CH?_"1^&[^Q7B22/,9]''*G\Q618;?'W@!(I#Y=TT?E/GK%<)W_P"^A^M=
MASZ8KBM1#>!?$,NIHI.AZBX^V!1_Q[S=!+C^Z>A_.NRC)RCR+XD[KUZKY_H>
M?7BHR]I+X6K2].C^7ZWZ$L%Q<^(-+M-1@4)KNEN8YX"<;FZ21GV8`$'Z59A:
M.Y@EO+*-[BQN&S<V@XDAD'5E'9AQD>V14VK:5<)>+K.C,ANRH$\!;$=VG8$]
MF'9OPZ57M)K/6[M[BSGDTG6%`$\#@*Y]G0\-[-^5:735X[?EY/ROLS*SB^66
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MZE?>,O$&OM"I6."_N!Y0!'=1U_&MGXF?#VV^)GA@Z+=W<UG$9XY_-@`+94Y`
MY[5UU%`%:SMA9VL,"DLL:*@)ZD``?TKS[Q=\"=#\2ZY)KMG<WWAW79%P]_I,
M_E,_NR]&/N:]*HH`X'P-\+[CPCJSZC>^*];\17!B,2KJ4P,:`G.0HXS[UQEA
M^S7<Z*+B/2OB#XCTJVFF><V]HT:)N8Y)QBO<:*`/-E^#D=U<^$9M5U[4=8/A
MV1[B/[7M)N)B>'D/JHX&*]&P<=3^=/HH`XGPI\,K7PAXN\1ZU9WDQAUMUEFL
M&5?*209RR]\G)SFN=U?]GK26U:YU/P[JVJ^$+RY.Z;^R)]D3GKGRSP,UZQ10
M!Y]H'PH.D:'KEC>>(]8UN;5K<V\MSJ$P=HQM890=!]X_D*X[2/V:[[0=-@T_
M3?B1XGL;&!=D5O`\:H@]`,<5[E10!YEXZ^"L?CSPWX?TR\U_48[C1Y%F34$V
M&>20*0'8GOSG(JOX;^#.KZ%KMEJ$_P`1/$NJ16\@=K.[E0Q2C^ZP`Z5ZK10`
MS%/HHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`$/2FX.>OY&GT
M4`-48IU%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%,(I]%`
M#5'K3J**`"BBB@!".*AF@CN(GBE19(G!5D89!![&IZ0]*`W.,CT[4_!3G^S(
MWU31"<_8-W[^V]?+)^\O^R?PJY%>^'_&D:AC%+<1<;)/W<\)].S+^%=(1GC%
M9NJ>&],UIE>]LXII5Z2XVR#Z,.1^==2JJ3O/1]UO\^_X'$Z,H+EIV<>SV^3Z
M?CY6*\?AVYMB?LVLWT2]EDVR@#ZL":;)X;N+EA]JUF_F7NL96$'\4`-0'P5%
M&,6VJZI:J.@2Y+@>WS9I/^$(BF!6YU;5+I"?NM<[!_XZ!5\\=^?\-?Z^9')+
M;V?_`)-I_7R$>Z\.>"4)W06TTG4*?,GE/IW9J+"XUK7[Z&X,3:-I43!Q%(`;
MBY_WA_`OMUK0TKPKI.BN9+.QBAE/64C?(?\`@1R?UK6'%9RJ1^RKON_\O^'-
M(TINRDTEV7^?_##A2T45S'8%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`F*,4M%`"8HQ2T4`)BC%+10`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!15'6]4CT32;R_E5GCMH6F94ZD*,X%<)H?QB74+C1OMVC7&F66L,4
MLKMI%=78=F`Y6@#TBEI@.>]./2@`S2UQGB[X@OX;U[3-%M=+EU34=05FB19%
MC4!>N2:N>"?'%OXTM;MH[>:SN[.8P7-K-C=&_P!1U%`'3TF:13FAC[T`+2UY
M[X-^*-UXTOS':>'KI+!)F@EO6F7;&P]1U->@9]Z`'44AKB?$?Q&?2_$BZ%IF
MCW&MZDL/VB:.%U01)ZY/4^U`';9I:@MI7GMXI'C:%F4,8VZJ2,X/TJ;M0`45
MS_C3QC:>"-#DU*[628!UCCAB^](YZ**D\+ZWJ&MVLLFH:/-HTJL`L<TBOO!&
M<@B@#=HIJGFG4`%%%%`!12,<"O+A\;T%M=ZBVA78T.TNC:3WPD4E&!P24ZXH
M`]1I:AM[A+F".:-M\<BAU;U!&14H.:`"EKE?B!XYC\!:-'J$MI)>AYEA$<3`
M')^M:'A?6;_6K-YK_2)M'D#[5BF=7+#'WN*`-JBBH;N?[-;R2D%@B%R!WP,T
M`345S/@#QK'X\\/KJL5L]HAE:/RY&!/'>NFH`*2@\`UY_>_%"Z7QA?>'].\/
MW6IW%F%>62.55`4]^?K0!Z#138V+*"1M.,XIU`"4M8GB_P`30>$/#]YJMPC2
MI;KD1*>7/91]:B\$>+8/&WAZWU6WC:!9"RM"YRR,#@@T`=!1136Z4`+2UPB?
M$R34?$MWI>D:)=:I!93+!=WL;JJ1,?0$Y.*[G-`#J2@=*Y'X@>/U\"QZ9FPE
MU&6_N#;Q1Q,%.[&1UH`ZZEK*\/:G>ZKIJW%]ILNE3EB#;2N'8`=#D<<UIK0`
MZBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHII)S0`ZBFC-.H`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@#GO'_P#R)6N_]>4O_H)KSCX6^`&\0>'O"NK:EJDES9V(,UIIZQA4
M1LD9+9RU>S21K*I5E#*1@@C((IL4*0($C18T'15&`/PH`<%XI3TI:0]*`/&?
MBL+]_BEX472I8X=2^S3F!I4W+N`/!'OT_&MKX%36%SX;O)HU==9>Y;^U!*<O
MYX)_\=]/QKT=K:)Y5E:-&D7[KE06'T-$5I#`[O'$D;.<LRJ`6^OK0!(M(W]*
M<!BD*YH`^?\`X%7EC%JMQ'+XAFMKM[V81Z0'`CGS_$1ZU[^!FJZ:7:12B5+6
M!)`<AUB4,/QJT!B@!&Z5XA\;)]&TG5VU;3M:ETSQE;1*$MH`2;E2?E4C&#7N
M!&:KR:=;33K-);Q22K]V1T!8?0T`4O#5U>7WA_3I]0C\J]E@1YDQC#$<\=OI
M6KVI,4Z@#COBC:>'[_PK+!XDNOL5B\BA+D9!CD_A((KF?@3K>IZG::Q;7%Y+
MJNE6<XBL;^9<-*F/U%>HW%K%=QF.:))HSU210P/X&EAMH[>-8XD6.->B(H`'
MX"@!ZTZF@8IU`!1110`U_NU\L:=//%H4YOY"_A&;7Y8M1CA&'!W?*2W]W/4>
MU?5!&:K_`-GVWE/%]GB\MSED\L;6/J1WH`+/R1:PBW*^1L7RRO3;CC'X8JP#
M35C"*%4!5`P`.`*<!B@#R?\`:-(7P3;;FV#[=%EO3WKKOAW=6-QHK"QU^;Q%
M&DA#7,[AF4XSM_"NEN+:*Z39+$DJYSM=0P_6BWM(;12L,,<*DY(C0*"?PH`F
MJGJW_(-NO^N+_P#H)JY2%0PP1D4`>/\`[._B/3#X4CT<7D7]I^=++]ES\^WC
MFO8!5:'3;6WD$D5M#%)C&Y(P#^8JU0`C?=->`7=U8VOQOU][[Q!-H"!(BLD+
MA?..1^[/M7T!56;2[2>0R26L$CDYW/$I/YF@">-@R@@[@0#FE)I0,4F,T`>6
M_&"]N-1UCPUX>LK;[?//<_;9K4.%WQQ]B3T&:J?"&_N-(\7>*?#U]:_V?,\W
M]HPVN\,$5^H!'4=*]::VB:82F-#*!@/M&X#TS2?98O/,WE)YI&/,VC=CTS0!
M)G%#=*`M*1F@#Y^\8:A8>'/'L5[X-U>5M;N[Y8;_`$B)2R.?XF(Q]/SS7OL9
M9D&X8;'(]ZC73[9+@W"V\2SGK*(QN/XU/MH`4#`KQW]HED6+PH9;AK2/^TCN
MG4X,8V?>'TKV+'%0W%G#=@">&.8`Y`D0,!^=`&)X(N;2Y\/PFRUB37859E^W
M3-N9SDY!(].E=`*C@M8K:/9#&D*#G;&H4?D*E`Q0`M%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`444W=B@!U%-!YIU`!1110`4444`%%%%`!6;K
MD>IRVJC2IK:"XWC+7*%EVXYX'?I6E10!R/V3QG_T$-(_[\/1]E\9_P#/_I'_
M`'X>NNHH`Y'[+XS_`.?_`$C_`+\/1]E\9_\`/_I'_?AZZZB@#D?LOC/_`)_]
M(_[\/1]E\9_\_P#I'_?AZZZB@#D?LOC/_G_TC_OP]'V7QG_S_P"D?]^'KKJ*
M`.1^R^,_^?\`TC_OP]'V7QG_`,_^D?\`?AZZZB@#D?LOC/\`Y_\`2/\`OP]'
MV7QG_P`_^D?]^'KKJ*`.1^R^,_\`G_TC_OP]'V7QG_S_`.D?]^'KKJ*`.1^R
M^,_^?_2/^_#T?9?&?_/_`*1_WX>NNHH`Y'[+XS_Y_P#2/^_#T?9?&?\`S_Z1
M_P!^'KKJ*`.1^R^,_P#G_P!(_P"_#T?9?&?_`#_Z1_WX>NNHH`Y'[+XS_P"?
M_2/^_#T?9?&?_/\`Z1_WX>NNHH`Y'[+XS_Y_](_[\/1]E\9_\_\`I'_?AZZZ
MB@#D?LOC/_G_`-(_[\/1]E\9_P#/_I'_`'X>NNHH`Y'[+XS_`.?_`$C_`+\/
M1]E\9_\`/_I'_?AZZZB@#D?LOC/_`)_](_[\/1]E\9_\_P#I'_?AZZZB@#D?
MLOC/_G_TC_OP]'V7QG_S_P"D?]^'KKJ*`.1^R^,_^?\`TC_OP]'V7QG_`,_^
MD?\`?AZZZB@#D?LOC/\`Y_\`2/\`OP]'V7QG_P`_^D?]^'KKJ*`.1^R^,_\`
MG_TC_OP]'V7QG_S_`.D?]^'KKJ*`.1^R^,_^?_2/^_#T?9?&?_/_`*1_WX>N
MNHH`Y'[+XS_Y_P#2/^_#T?9?&?\`S_Z1_P!^'KKJ*`.1^R^,_P#G_P!(_P"_
M#T?9?&?_`#_Z1_WX>NNHH`Y'[+XS_P"?_2/^_#T?9?&?_/\`Z1_WX>NNHH`Y
M'[+XS_Y_](_[\/1]E\9_\_\`I'_?AZZZB@#D?LOC/_G_`-(_[\/1]E\9_P#/
M_I'_`'X>NNHH`Y'[+XS_`.?_`$C_`+\/1]E\9_\`/_I'_?AZZZB@#D?LOC/_
M`)_](_[\/1]E\9_\_P#I'_?AZZZB@#D?LOC/_G_TC_OP]'V7QG_S_P"D?]^'
MKKJ*`.1^R^,_^?\`TC_OP]'V7QG_`,_^D?\`?AZZZB@#D?LOC/\`Y_\`2/\`
MOP]'V7QG_P`_^D?]^'KKJ*`.1^R^,_\`G_TC_OP]'V7QG_S_`.D?]^'KKJ*`
M.1^R^,_^?_2/^_#T?9?&?_/_`*1_WX>NNHH`Y'[+XS_Y_P#2/^_#T?9?&?\`
MS_Z1_P!^'KKJ*`.1^R^,_P#G_P!(_P"_#T?9?&?_`#_Z1_WX>NNHH`Y'[+XS
M_P"?_2/^_#T?9?&?_/\`Z1_WX>NNHH`Y'[+XS_Y_](_[\/1]E\9_\_\`I'_?
MAZZZB@#D?LOC/_G_`-(_[\/1]E\9_P#/_I'_`'X>NNHH`Y'[+XS_`.?_`$C_
M`+\/1]E\9_\`/_I'_?AZZZB@#D?LOC/_`)_](_[\/1]E\9_\_P#I'_?AZZZB
M@#D?LOC/_G_TC_OP]:NA0ZU&)O[7N+2<G'E_98V7'KG/X5LT4`-`IU%%`!11
%10!__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
